Morgan Stanley analyst Lauren Schenk maintains Rover Group (NASDAQ:ROVR) with a Equal-Weight and raises the price target from $4.8 to $6.
NLS Pharma Shares Fall After Mazindol ER Interim Data Shows 39% Improvement On Sleepiness Scale
NLS Pharmaceutics Ltd (NASDAQ:NLSP) has announced interim topline data from its Phase 2a trial of its lead product candidate, Quilience (Mazindol…